TechCrunch : Teradar reveals its first terahertz-band vision sensor for cars

Teradar reveals its first terahertz-band vision sensor for cars

Two months after coming out of stealth with a $150 million fundraise, Boston-based Teradar is showing off its first flagship terahertz sensor at Consumer Electronics Show 2026 this week. The company is positioning the sensor, called Summit, as the first long-range, high-resolution sensor of its kind “designed for high performance in any type of weather, filling a critical gap left by legacy radar and lidar sensors.”

The sensor will start shipping until 2028 if Teradar can lock down contracts with automakers. If that happens, the company expects the Summit will help enable those companies to add partial, or even full, autonomy features to their vehicles.

Teradar’s whole approach is about leveraging the relatively-unused terahertz band of the electromagnetic spectrum between microwaves and infrared. And it’s a solid-state sensor, meaning there are no moving parts. All this is meant to give Teradar’s sensor the best qualities of lidar and radar sensors, with few of the drawbacks.

It’s a potentially attractive proposition for automakers who might wince at the cost of lidars or the limitations of radars. Teradar says it’s already working to prove its tech with five top automakers from the U.S. and Europe, and three Tier 1 suppliers.

Teradar’s impending entry into the market comes at a pivotal moment for automotive sensor suppliers. Leading U.S. lidar company Luminar just filed for bankruptcy protection in December after contracts with Volvo and Mercedes-Benz fell apart, as the automakers backed away from the tech.


Those deals also crumbled partly because of low-cost competition from China, according to Luminar. Lidar adoption has been strong in China’s auto market and shows little sign of slowing up. In October, Chinese lidar company Hesai said it had built more than 1 million lidar sensors in 2025.

Other U.S. companies in the space, like Ouster (acquired and merged with rival Velodyne after a wave of consolidation) have diversified into potential markets like robotics and smart infrastructure.

Teradar is looking beyond automotive, too, and that vision was reflected in its recent raise. The $150 million Series B included funding from Lockheed Martin’s venture arm, and VXI Capital, a new defense-focused fund led by the former CTO of the U.S. military’s Defense Innovation Unit.

Lidar isn’t completely dead in the auto industry, however. Rivian in December said it would integrate a roof-mounted lidar sensor (from an unnamed supplier) in its upcoming R2 SUV, signaling that there is still an appetite for using advanced sensor technology to bring autonomy to passenger vehicles, especially if it’s affordable.

Teradar CEO Matt Carey told TechCrunch in November that he believes his terahertz sensor can meet all those marks, and sounded eager to pounce on the opportunity.

“Our main job is to make sure our sensor gets on all automobiles, and whatever the best way to do that is, that’s what we’re going to pursue,” he said.

WWD : Ermenegildo Zegna Group’s New Chapter Post Handover

Ermenegildo Zegna Group’s New Chapter Post Handover
Effective Jan. 1, brothers Angelo and Edoardo Zegna are tasked with leading the Zegna brand forward as CEOs while their father Gildo has assumed the role of executive chairman.

Effective Jan. 1, Gildo Zegna, undoubtedly instrumental in shaping the Ermenegildo Zegna Group into the international, publicly listed company it is today and driving it into the 21st century, passed the baton to his two sons.

Although not entirely unexpected, this was a forward-looking choice that stood out in an industry where the generational handover is often not a top priority. However, it is one that must be planned “bravely, when you are in good health, and have the right energy,” said Gildo Zegna at the end of November, when he revealed he would become executive chairman of the group, which in addition to the Zegna brand also comprises Thom Browne and Tom Ford Fashion, in addition to the textile segment.

Zegna, who has led the group since 2006 and was previously group chairman and chief executive officer, turned 70 on Sept. 30 and said that he had started working on the handover plan two years ago, and more actively over the past year.

Chief financial officer Gianluca Tagliabue took on the role of CEO of the group on Jan. 1.

Gildo Zegna’s sons Angelo and Edoardo, members of the family’s fourth generation, were named co-CEOs of the Zegna brand, reporting to Tagliabue.

What will the group look like under their leadership? According to their father, they are “complementary and naturally balance each other out. They don’t compete with one another. Edoardo is more extroverted and very rational, Angelo is more execution-driven. They will play for the team with no ego. They have a clear vision and they will continue the family legacy, having demonstrated their business leadership over the past years. Together, they will not only carry forward the brand’s timeless heritage, but strengthen it further.”

It is true their expertise and different skills were developed over the years, also outside the family company.

Edoardo Zegna, 39, has lived in Washington, New York and San Francisco and is currently based in London. He has worked at Gap Inc. with the creative concept team in New York from 2009 to 2011 and after that, from 2011 to 2014, he was head of product at the American fashion brand Everlane and one of the first employees of that company.

He was appointed head of content and innovation and omnichannel at the Ermenegildo Zegna Group in 2014, later becoming chief marketing and digital officer of Zegna as well as group chief sustainability officer. He greatly contributed to Zegna’s One Brand strategy; the entirely traceable Oasi Cashmere collections; the Zegna X digital customization tool aimed at raising the bar of luxury service, and the exclusive Villa Zegna experiences. As co-CEO of Zegna, he will lead all aspects of brand strategy, from brand image to marketing, and, together with Zegna’s artistic director Alessandro Sartori, design matters, including store design.

Angelo Zegna, 37, held the role of CEO of Zegna’s Europe, Middle East and Africa region and global event strategy director and global client strategy director, and as co-CEO he will oversee product development, merchandising and commercial strategy, driving performance across markets and channels.

Earlier in his career he oversaw Zegna’s retail business in the U.S., spearheading transformative programs focused on client experience and commercial excellence, such as an app to offer personalized styling remotely.

Before that he contributed to strategic and operational projects at Luxottica in São Paulo and New York and worked as a consultant with Bain & Company in Mumbai, where he focused on strategy and performance improvement across emerging markets.

As for Tagliabue, before talking on his CFO role, he was chief operating officer, overseeing the supply chain, a key position for Zegna. He’s now tasked with further integrating Thom Browne and Tom Ford Fashion into the group.

In his new role as executive chairman, Gildo Zegna will continue to oversee the group’s textile platform, the foundations of the company.

As well as the group’s textile division, he will oversee the group general counsel’s office (including internal audit), and the external relations department, which encompasses sustainability, investor relations and corporate communications.

The executive has been instrumental in shaping the Zegna group into an international powerhouse with 2024 sales of 1.94 billion euros; selecting Sartori, who has been successfully evolving Zegna’s style; taking control of the Thom Browne brand in 2018; inking a long-term agreement with the Estée Lauder Cos. Inc. in 2023 for the production and distribution of the Tom Ford Fashion label, and publicly listing the group on the New York Stock Exchange in December 2021.

FT : Novo Nordisk launches price war over weight-loss pills

Novo Nordisk launches price war over weight-loss pills
Lowest doses of Wegovy in oral form will start at $149 a month for US users until April

Novo Nordisk is launching a weight-loss pill price war as it seeks to keep pace with arch-rival Eli Lilly in the market for GLP-1 drugs.

The Danish drugmaker announced on Monday that patients could purchase the lowest 1.5mg and 4mg doses of its Wegovy pill for $149 a month in the US until April, when the 4mg dose will rise to $199 a month. Patients with insurance can pay as little as $25 a month for the lowest doses.

Higher doses of the drug at 9mg and 25mg are priced at $299 for a month-long supply.

Shares in the Copenhagen-listed company rose more than 2 per cent on Monday following the announcement, but have fallen 45 per cent over the past 12 months.

The Wegovy pill costs significantly less than Novo’s injectable version of the drug and Lilly’s own injectable, Zepbound, which dominate the market. Both drugs cost more than $1,000 a month but the price will be cut to about $350 when TrumpRx, the medicine purchasing website proposed by US President Donald Trump, launches later this year.

The pricing announcement comes weeks after the oral version of Wegovy was approved by the US Food and Drug Administration, marking the first regulatory nod for a weight-loss treatment in pill form.

The lower prices signal the start of a race to attract more patients who are overweight or obese. The pill resulted in an average weight loss of about 17 per cent of body weight after 64 weeks, according to trial results announced by Novo.

The pill must be taken daily on an empty stomach. Users have to wait at least 30 minutes before eating, drinking or taking other oral medications in order to give the pill time to absorb, according to the company’s instructions.

Lilly’s weight-loss pill, orforglipron, is expected to be approved by the US regulator this year. The White House said last year that it had reached a deal with Lilly for orforglipron to cost $346 a month when purchased through TrumpRx.

Orforglipron has had mixed fortunes in clinical trials. It disappointed in a trial of people without diabetes, delivering an average weight loss of 12.4 per cent of body weight, which was at the lower end of analysts’ expectations.

However, the drug met the company’s targets in achieving 10.5 per cent weight reduction in overweight people with diabetes.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • DVLT +22.8%, KZIA +22%, GHRS +20.5%, PBF +16.7%, QXO +9.1%, NMRA +9%, ALMS +7.8%, CVX +7.3%, COP +7.2%, ATRA +6.9%, POWW +6.6%, NVA +5%, XLE +4.7%, XOM +4.5%, CRWV +4%, FFAI +3.7%, RIOT +3.5%, CNCK +3.4%, ZURA +3.4%, PLAB +2.8%, BBAI +2.1%, OXY +2.1%, KDK +1.6%, DVN +1.5%, CANG +1.4%, NOC +1.3%, LMT +1.1%, GD +0.9%, HIMX +0.8%, LHX +0.7%
  • Gapping down:
    • NXXT -6%, AVR -5.3%, CRNX -1.6%, PB -1.5%, BWIN -1.1%, GSK -1%, BNR -1%, SNY -1%, NIU -1%

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Agilent (A) upgraded to Outperform from In Line at Evercore ISI, tgt $160
    • Alerus Financial (ALRS) upgraded to Strong Buy from Outperform at Raymond James, tgt $27
    • American Tower (AMT) upgraded to Buy from Neutral at New Street, tgt $203
    • Arista Networks (ANET) upgraded to Overweight from Neutral at Piper Sandler, tgt $159
    • Arm (ARM) upgraded to Outperform from Neutral at Oddo BHF, tgt $170
    • ASML (ASML) upgraded to Outperform from Market Perform at Bernstein, tgt $1,528
    • Azenta (AZTA) upgraded to Outperform from In Line at Evercore ISI, tgt $50
    • Centene (CNC) upgraded to Overweight from Equal Weight at Barclays, tgt $54
    • Church & Dwight (CHD) upgraded to Outperform from Market Perform at Raymond James, tgt $100
    • Citizens Financial (CFG) upgraded to Overweight from Equal Weight at Barclays, tgt $77
    • Coinbase (COIN) upgraded to Buy from Neutral at Goldman, tgt $303
    • Continental AG (CTTAY) upgraded to Market Perform from Underperform at Bernstein
    • Costco (COST) upgraded to Outperform from Neutral at Mizuho, tgt $1,000
    • CoreWeave (CRWV) upgraded to Neutral from Underperform at DA Davidson, tgt $68
    • Cullen/Frost (CFR) upgraded to Outperform from Market Perform at Keefe Bruyette, tgt $150
    • Dover (DOV) upgraded to Buy from Neutral at UBS, tgt $256
    • Duolingo (DUOL) upgraded to Buy from Neutral at BofA Securities, tgt $250
    • Emerson (EMR) upgraded to Buy from Neutral at UBS, tgt $168
    • Enphase Energy (ENPH) upgraded to Sector Weight from Underweight at KeyBanc
    • Equitable Holdings (EQH) upgraded to Overweight from Neutral at JPMorgan, tgt $60
    • Excelerate Energy (EE) upgraded to Strong Buy from Outperform at Raymond James, tgt $36
    • F5 (FFIV) upgraded to Outperform from Sector Perform at RBC Capital, tgt $325
    • F5 (FFIV) upgraded to Overweight from Neutral at Piper Sandler, tgt $295
    • First Industrial Realty (FR) upgraded to Buy from Hold at Deutsche Bank, tgt $67
    • Hershey (HSY) upgraded to Equal Weight from Underweight at Wells Fargo, tgt $182
    • HII (HII) upgraded to Buy from Hold at Melius Research
    • IBM (IBM) upgraded to Buy from Hold at Jefferies, tgt $360
    • Intel (INTC) upgraded to Buy from Hold at Melius Research, tgt $50
    • iRhythm (IRTC) upgraded to Outperform from In Line at Evercore ISI, tgt $210
    • Ironwood Pharmaceuticals (IRWD) upgraded to Outperform from Market Perform at Citizens, tgt $8
    • Kinetik Holdings (KNTK) upgraded to Outperform from Market Perform at Raymond James, tgt $46
    • Marvell (MRVL) upgraded to Buy from Hold at Melius Research, tgt $135
    • Mobileye (MBLY) upgraded to Overweight from Equal Weight at Barclays, tgt $16
    • Moody's (MCO) upgraded to Buy from Hold at Stifel, tgt $574
    • Motorola Solutions (MSI) upgraded to Overweight from Neutral at Piper Sandler, tgt $443
    • Oscar Health (OSCR) upgraded to Equal Weight from Underweight at Barclays, tgt $18
    • Palo Alto Networks (PANW) upgraded to Neutral from Sell at Guggenheim
    • Pinnacle Financial (PNFP) upgraded to Overweight from Neutral at Piper Sandler, tgt $120
    • Procore (PCOR) upgraded to Overweight from Equal Weight at Barclays, tgt $90
    • Sight Sciences (SGHT) upgraded to Overweight from Neutral at Piper Sandler, tgt $9
    • Sonoco (SON) upgraded to Buy from Neutral at BofA Securities, tgt $60
    • Sunoco LP (SUN) upgraded to Strong Buy from Outperform at Raymond James, tgt $70
    • SunocoCorp (SUNC) upgraded to Strong Buy from Outperform at Raymond James, tgt $70
    • Tactile Systems (TCMD) upgraded to Overweight from Neutral at Piper Sandler, tgt $35
    • United Rentals (URI) upgraded to Buy from Neutral at UBS, tgt $1,025
    • Varonis (VRNS) upgraded to Overweight from Neutral at Piper Sandler, tgt $47
    • WaterBridge Infrastructure (WBI) upgraded to Strong Buy from Outperform at Raymond James, tgt $30
    • Woodward (WWD) upgraded to Buy from Hold at Melius Research
    • Zimmer Biomet (ZBH) upgraded to Outperform from In Line at Evercore ISI, tgt $210
  • Downgrades:
    • Adobe (ADBE) downgraded to Hold from Buy at Jefferies, tgt $400
    • Alstom (ALSMY) downgraded to Hold from Buy at Kepler Cheuvreux
    • AutoZone (AZO) downgraded to Neutral from Outperform at Mizuho, tgt $3,550
    • Avantor (AVTR) downgraded to In Line from Outperform at Evercore ISI, tgt $12
    • Bausch + Lomb (BLCO) downgraded to In Line from Outperform at Evercore ISI, tgt $18
    • Crown Castle (CCI) downgraded to Neutral from Buy at New Street, tgt $93
    • Domino's Pizza (DPZ) downgraded to Hold from Buy at TD Cowen, tgt $460
    • EastGroup Properties (EGP) downgraded to Hold from Buy at Deutsche Bank, tgt $185
    • Enterprise Products (EPD) downgraded to Outperform from Strong Buy at Raymond James, tgt $36
    • Eaton (ETN) downgraded to Neutral from Buy at UBS, tgt $360
    • eToro (ETOR) downgraded to Neutral from Buy at Goldman, tgt $39
    • EverCommerce (EVCM) downgraded to Sector Perform from Outperform at RBC Capital, tgt $12
    • Exact Sciences (EXAS) downgraded to In Line from Outperform at Evercore ISI, tgt $105
    • Exelixis (EXEL) downgraded to Underperform from Neutral at BofA Securities, tgt $41
    • Five9 (FIVN) downgraded to Neutral from Overweight at Piper Sandler, tgt $21
    • Fortive (FTV) downgraded to Underperform from Outperform at Mizuho, tgt $51
    • Guardant Health (GH) downgraded to In Line from Outperform at Evercore ISI, tgt $105
    • Gulfport Energy (GPOR) downgraded to Peer Perform from Outperform at Wolfe Research
    • Hess Midstream (HESM) downgraded to Market Perform from Outperform at Raymond James
    • Hologic (HOLX) downgraded to In Line from Outperform at Evercore ISI, tgt $78
    • Life360 (LIF) downgraded to Market Perform from Outperform at Citizens
    • MPLX (MPLX) downgraded to Market Perform from Outperform at Raymond James
    • Omnicom (OMC) downgraded to Underperform from Neutral at BofA Securities, tgt $77
    • PagerDuty (PD) downgraded to Sector Perform from Outperform at RBC Capital, tgt $15
    • Pentair (PNR) downgraded to Sell from Hold at TD Cowen, tgt $90
    • Principal Financial (PFG) downgraded to Neutral from Overweight at JPMorgan, tgt $103
    • Rapid7 (RPD) downgraded to Underweight from Equal Weight at Barclays, tgt $15
    • Roper Technologies (ROP) downgraded to Underperform from Neutral at Mizuho, tgt $419
    • RTX (RTX) downgraded to Neutral from Buy at UBS, tgt $199
    • SentinelOne (S) downgraded to Neutral from Overweight at Piper Sandler, tgt $17
    • State Street (STT) downgraded to Equal Weight from Overweight at Barclays, tgt $152
    • Truist Financial (TFC) downgraded to Underweight from Equal Weight at Barclays, tgt $56
    • Twilio (TWLO) downgraded to Neutral from Overweight at Piper Sandler, tgt $148
    • Uber (UBER) downgraded to Sell from Hold at Melius Research, tgt $73
  • Others:
    • Akari Therapeutics (AKTX) initiated with a Buy at Ladenburg, tgt $1
    • Bitmine Immersion (BMNR) initiated with an Overweight at Cantor Fitzgerald, tgt $39
    • Cardinal Infrastructure (CDNL) initiated with an Outperform at William Blair
    • Cardinal Infrastructure (CDNL) initiated with a Buy at Stifel, tgt $28
    • Compass Therapeutics (CMPX) initiated with an Outperform at William Blair
    • Eastern Bankshares (EBC) initiated with an Outperform at Hovde Group, tgt $22.50
    • Lumexa Imaging (LMRI) initiated with a Buy at Deutsche Bank, tgt $22
    • Lumexa Imaging (LMRI) initiated with an Outperform at Leerink, tgt $23
    • Lumexa Imaging (LMRI) initiated with an Outperform at Raymond James, tgt $23
    • Lumexa Imaging (LMRI) initiated with an Outperform at William Blair
    • Lumexa Imaging (LMRI) initiated with an Overweight at Wells Fargo, tgt $22
    • Lumexa Imaging (LMRI) initiated with a Buy at Jefferies, tgt $23
    • MediciNova (MNOV) initiated with a Buy at Lucid Capital, tgt $11
    • Pinnacle Financial (PNFP) initiated with a Neutral at DA Davidson, tgt $110
    • SharpLink Gaming (SBET) initiated with an Overweight at Cantor Fitzgerald, tgt $15
    • SuRo Capital (SSSS) initiated with a Buy at Lucid Capital, tgt $12
    • vTv Therapeutics (VTVT) initiated with a Buy at TD Cowen, tgt $67
    • Waters (WAT) initiated with an Outperform at William Blair
    • Watts Water (WTS) initiated with a Sector Perform at RBC Capital, tgt $288
    • Zurn Elkay Water (ZWS) initiated with a Sector Perform at RBC Capital, tgt $49

>>> US Gapping up

Gapping up
Select metals/mining stocks trading higher:
  • ACH +4.3%, SLV +3.4%, AG +2.9%, EXK +2.8%, AU +2.5%, NG +2.2%, SA +2.2%, PAAS +2.2%, HL +2.2%, GOLD +2%, GLD +1.9%, GDX +1.9%, GFI +1.9%, HMY +1.9%, IAG +1.9%, KGC +1.7%, AA +1.7%, NEM +1.6%, AEM +1.4%, PAA +1.3%
Select oil/gas related names showing strength:
  • CVX +6.5%, COP +5.1%, XLE +4.1%, XOM +3.2%, OXY +2%, DVN +0.9%, USO +0.6%
Other news:
  • DVLT +22.8% (entered into a Master Purchase Order Agreement with AP Global)
  • KZIA +22.6% (shares reopened after being halted on Friday)
  • GHRS +16.2% (cleared to advance GH001 toward global Phase 3 in 2026)
  • PBF +12.8% (provides update on Martinez refinery operations)
  • ARBE +12.5% (combining Arbe's radar technology with NVIDIA (NVDA) accelerated computing)
  • ATRA +8.6% (amends commercialization agreement with Pierre Fabre Medicament)
  • NMRA +8.4% (reports results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation; highlights 2026 pipeline strategy and anticipated upcoming milestones)
  • POWW +7.2% (announces authorization of share repurchase program)
  • CBUS +6.9% (Cibus Global and Interoc advance herbicide-tolerant rice commercialization in Latin America)
  • QXO +5.9% (secures $1.2 bln preferred equity commitment to support acquisitions)
  • NVA +5.3% (response to media article regarding Pakistani antimony concentrate)
  • PLX +5.2% (provides several updates in letter to stockholders)
  • CRWV +4.2% (disclosed amended credit agreement)
  • RIOT +3.7% (names Jason Chung as CFO)
  • FFAI +3.7% (enters into warrant termination agreements)
  • CNCK +3.4% (files for $200 mln mixed securities shelf offering)
  • ZURA +3.2% (entered into several agreements, issued shares)
  • GYRE +2.8% (aligns with China CDE on conditional approval pathway for hydronidone)
  • PLAB +2.1% (announcess that Chief Technology Officer Christopher Progler will be stepping away from his current role with the company as part of a planned leadership transition following more than 20 years of service)
  • JBIO +2% (outlines key 2026 objectives and strategy to advance pipeline of potentially best-in-class monoclonal antibodies across multiple autoimmune diseases ahead of the 44th Annual J.P. Morgan Healthcare Conference)
  • BBAI +1.9% (expects to eliminate approximately $125 million of debt through a combination of voluntary conversions by noteholders and the Company's redemption of any Notes that have not been converted through the Redemption Date)
  • RANI +1.5% (entered into a securities purchase agreement; adopted amended and restated bylaws)
  • CANG +1.4% (reports December 2025 bitcoin production update)
  • HIMX +1.3% (confirms CPO collaboration and strategic partnership with FOCI remain unchanged)
  • IMDX +1% (prepares for U.S. commercial launch of GraftAssuredx as clinical trial nears completion)

>>> US Gapping down

Gapping down
Other news:
  • NXXT -6% (subsidiary served with a complaint alleging default under a promissory note)
  • AVR -5.3% (files for $500 mln mixed securities shelf offering)
  • CRNX -3.7% (to provide PALSONIFY business update and announce topline results from fourth cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia)
  • PB -1.5% (completes merger with American Bank Holding)
  • BWIN -1.1% (completes merger transaction with CAC Group)

>>> Europe : Brokers Upgrades & Downgrades - 5th of January 2026 V2(+)

>>> Up
* ARM Holdings ADRs Raised to Outperform at Oddo BHF; PT $170
* ASML Raised to Outperform at Bernstein; PT 1,300 euros (+)
* Canal PT raised from 370p to 400p at BofA ML
* Coinbase Raised to Buy at Goldman; PT $303
* Comet Raised to Buy at Bank Vontobel; PT 275 Swiss francs (+)
* Continental Raised to Market Perform at Bernstein (+)
* DKSH Raised to Neutral at BNP Paribas; PT 57 Swiss francs
* Dover Raised to Buy at UBS; PT $256
* Emerson Electric Raised to Buy at UBS; PT $168
* Enphase Energy Raised to Sector Weight at KeyBanc
* Eurofins Scientific Raised to Outperform at BNP Paribas
* Evonik Raised to Equal-Weight at Morgan Stanley; PT 14.70 euros
* IBM Raised to Buy at Jefferies; PT $360
* Johnson Matthey Raised to Buy at Berenberg; PT 2,550 pence
* Luotea Oyj Raised to Accumulate at Inderes; PT 2.70 euros
* Motorola Solutions Raised to Overweight at Piper Sandler
* Nokia PT raised to 5.40 from 4.50 at Bernstein
* NNIT Raised to Hold at ABG; PT 50 kroner
* Palo Alto Networks Raised to Neutral at Guggenheim
* Partners Group Raised to Buy at Citi; PT 1,190 Swiss francs
* Pirelli Raised to Outperform at Bernstein (+)
* Redeia Raised to Equal-Weight at Barclays; PT 15 euros
* Vestas Raised to Buy at Fearnley; PT 205 kroner (+)

>>> Down
* Alstom Cut to Hold at Kepler Cheuvreux (+)
* Athens Intnl Airport Cut to Neutral at UBS; PT 10.70 euros
* Adobe Cut to Hold at Jefferies; PT $400
* Appeal for volunteers to listen to children read
* Banco BPM Cut to Underweight at Morgan Stanley; PT 14 euros
* Bunzl Cut to Neutral at BNP Paribas; PT 2,350 pence
* Eaton Corp Cut to Neutral at UBS; PT $360
* EToro Group Cut to Neutral at Goldman; PT $39
* Grainger PT Cut to 200 pence from 220 pence at Peel Hunt
* Ibstock Cut to Hold at Deutsche Bank; PT 144 pence
* Intertek ADRs Cut to Neutral at BNP Paribas; PT $69
* Intertek Cut to Neutral at BNP Paribas; PT 5,200 pence

>>> Initiation
* BPER Banca Rated New Overweight at Morgan Stanley
* Luotea Oyj Rated New Buy at SEB Equities; PT 9.30 euros (+)
* Monte Paschi Reinstated Equal-Weight at Morgan Stanley
* Watts Water Reinstated Sector Perform at RBC; PT $288
* Zurn Elkay Water Rated New Sector Perform at RBC; PT $49

>>> Call
* Bernstein Upgrades ASML, Cuts Besi Estimates: EMEA TMT Premarket (+)
* BPER Banca Top Italy Bank Pick at Morgan Stanley, Banco BPM Cut
* BofA Says Now’s the Time to Buy Health Care, Real Estate Stocks
* Eurofins Double Upgraded to Outperform at BNP Paribas on Outlook (+)
* AlphaValue/Baader Europe Updates Siltronic Model Post-Capital Markets Day
* Syensqo Favored Chemicals Pick, Evonik Raised at Morgan Stanley
* TSMC Rises as Goldman Lifts PT By 35% on AI Multi-Year Growth